Browsing Tag
Karyopharm Therapeutics Inc.
2 posts
Karyopharm Therapeutics (KPTI) tees up ASCO 2026 readout as SENTRY trial shifts myelofibrosis debate
Karyopharm is taking its Phase 3 SENTRY myelofibrosis data to ASCO 2026. Read why the late-breaking slot matters for KPTI and selinexor now.
Zevra Therapeutics appoints new CFO. Is the rare disease biotech entering its next commercial cycle?
Zevra Therapeutics appoints Justin Renz as CFO as the rare disease biotech prepares for commercialization expansion. Read what the leadership move signals.